| RESIDENTS PAGE |
|
| Year : 2016 | Volume
: 61
| Issue : 5 | Page : 550-553 |
|
|
Belimumab in systemic lupus erythematosus
Ankita Srivastava
Department of Skin and VD, RUHS College of Medical Sciences and Government RDBP Jaipuria Hospital, Jaipur, Rajasthan, India
Correspondence Address:
Ankita Srivastava
Department of Skin and VD, RUHS College of Medical Sciences, Jaipur, Rajasthan
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-5154.190107
|
|
|
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
